Familial hemiplegic migraine is a rare autosomal dominant disorder associated with stereotypic neurologic aura phenomena including hemiparesis. So far two chromosomal loci have been identified. Families linked to the chromosome 19 locus display missense mutations within the CACNL1A4 gene. Here we report on a family with familial hemiplegic migraine and cerebellar ataxia with recurrent episodes of acute paranoid psychosis with anxiety and visual hallucinations associated with migraine attacks. Based on the clinical and haplotype evidence indicating linkage to chromosome 19 in this family, we hypothesize that a dysfunction of the mutated calcium channel may be involved not only in the development of hemiplegic migraine but also in the acute psychotic episodes observed in these patients.

Keywords:
Migraine, Psychosis, Ataxia, Serotonin
1.
Ahmed-Mas, Reid E, Cooke A, Arngrimsson R, Tolmie JL, Stephenson JBP: Familial hemiplegic migraine in the west of Scotland: A clinical and genetic study of seven families. J Neurol Neurosurg Psychiatry 1996;61:616–620.
2.
Elliott MA, Peroutka SJ, Welch S, May EF: Familial hemiplegic migraine, nystagmus, and cerebellar atrophy. Ann Neurol 1996;39:100–106.
3.
Munte TF, Muller-Vahl H: Familial migraine coma: A case study. J Neurol 1990;237:59–61.
4.
Terwindt GM, Ophoff RA, Haan J, Frants RR, Ferrari MD: Familial hemiplegic migraine: A clinical comparison of families linked and unlinked to chromosome 19.DMG RG. Cephalalgia 1996;16:153–155.
5.
Joutel A, Tournier-Lasserve E, Bousser MG: Hemiplegic migraine. Presse Méd 1995;24:411–414.
6.
Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SMG, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJB, Hofker MH, Ferrari MD, Frants RR: Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca-channel gene CACNL1A4. Cell 1996;87:543–552.
7.
Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8:19–28.
8.
Joutel A, Ducros A, Vahedi K, Labauge P, Delrieu O, Pinsard N, Mancini J, Ponsot G, Gouttière F, Gastaut JL: Genetic heterogeneity of familial hemiplegic migraine. Am J Hum Genet 1994;55:1166–1172.
9.
Knight DE, von Grafenstein H, Athayde CM: Calcium-dependent and calcium-independent exocytosis. Trends Neurosci 1989;12:451–458.
10.
Frittoli E, Gobbi M, Mennini T: Involvement of P-type Ca2+ channels in the K(+)- and d-fenfluramine-induced (3H)5-HT release from rat hippocampal synaptosomes. Neuropharmacology 1994;33:833–835.
11.
Kimura M, Yamanishi Y, Hanada T, Kagaya T, Kuwada M, Watanabe T, Katayama K, Nishizawa Y: Involvement of P-type calcium channels in high potassium-elicited release of neurotransmitters from rat brain slices. Neuroscience 1995;66:609–615.
12.
Pullar IA, Findlay JD: Effects of voltage-sensitive calcium channel antagonists on the release of 5-hydroxytryptamine from rat hippocampus in vivo. J Neurochem 1992;59:553–559.
13.
Silberstein SD: Serotonin (5-HT) and migraine. Headache 1994;34:408–417.
14.
Iqbal N, van Praag HM: The role of serotonin in schizophrenia. Eur Neuropsychopharmacol 1995;5:11–23.
15.
Breier A: Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 1995;14:187–202.
16.
Fuller GN, Marshall A, Flint J, Lewis S, Wise RJ: Migraine madness: Recurrent psychosis after migraine. J Neurol Neurosurg Psychiatry 1993;56:416–418.
17.
Feeley MP, O’Hare J, Veale D, Callaghan N: Episodes of acute confusion or psychosis in familial hemiplegic migraine. Acta Neurol Scand 1982;65:369–375.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.